Treatment patterns in metastatic bladder cancer in Japan: results of the CancerMPact^® survey 2020.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2024-03-01 Epub Date: 2024-01-12 DOI:10.2217/fon-2023-0197

Ana Paula A Bueno, Otavio Clark, Matthew Turnure, Eloisa S Moreira, Akira Yuasa, Shigeru Sugiyama, Melissa Kirker, Si Li, Ningqi Hou, Jane Chang, Mairead Kearney, Gena Kanas

{"title":"Treatment patterns in metastatic bladder cancer in Japan: results of the CancerMPact® survey 2020.","authors":"Ana Paula A Bueno, Otavio Clark, Matthew Turnure, Eloisa S Moreira, Akira Yuasa, Shigeru Sugiyama, Melissa Kirker, Si Li, Ningqi Hou, Jane Chang, Mairead Kearney, Gena Kanas","doi":"10.2217/fon-2023-0197","DOIUrl":null,"url":null,"abstract":"Aim: To assess physician-reported treatment of metastatic bladder cancer in Japan. Methods: 76 physicians completed the CancerMPact® survey in July 2020, considering patients treated within 6 months. Results: Physicians treated a mean of 38.1 patients per month. Of cisplatin-eligible and -ineligible patients, 97.6 and 89.3%, respectively, received first-line platinum-based therapy, most commonly cisplatin plus gemcitabine (72.9%) and carboplatin plus gemcitabine (59.7%). 1.6 and 5.6% received first-line immune checkpoint inhibitors, respectively. 48.4 and 45.0%, respectively, progressed and received second-line therapy, most commonly with pembrolizumab (61.7%). Conclusion: In 2020, most patients with metastatic bladder cancer in Japan received first-line platinum-based chemotherapy; however, >50% received no subsequent treatment, highlighting the need for new treatment regimens to improve outcomes and maximize first-line treatment benefits.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"603-611"},"PeriodicalIF":3.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/fon-2023-0197","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To assess physician-reported treatment of metastatic bladder cancer in Japan. Methods: 76 physicians completed the CancerMPact^® survey in July 2020, considering patients treated within 6 months. Results: Physicians treated a mean of 38.1 patients per month. Of cisplatin-eligible and -ineligible patients, 97.6 and 89.3%, respectively, received first-line platinum-based therapy, most commonly cisplatin plus gemcitabine (72.9%) and carboplatin plus gemcitabine (59.7%). 1.6 and 5.6% received first-line immune checkpoint inhibitors, respectively. 48.4 and 45.0%, respectively, progressed and received second-line therapy, most commonly with pembrolizumab (61.7%). Conclusion: In 2020, most patients with metastatic bladder cancer in Japan received first-line platinum-based chemotherapy; however, >50% received no subsequent treatment, highlighting the need for new treatment regimens to improve outcomes and maximize first-line treatment benefits.

查看原文本刊更多论文

日本转移性膀胱癌的治疗模式：2020 年 CancerMPact® 调查结果。

目的：评估日本医生报告的转移性膀胱癌治疗情况。方法：2020 年 7 月，76 名医生完成了 CancerMPact® 调查，其中包括 6 个月内接受治疗的患者。结果医生平均每月治疗 38.1 名患者。符合顺铂治疗条件和不符合顺铂治疗条件的患者中，分别有 97.6% 和 89.3% 接受了一线铂类治疗，其中最常见的是顺铂联合吉西他滨（72.9%）和卡铂联合吉西他滨（59.7%）。分别有 1.6% 和 5.6% 的患者接受了一线免疫检查点抑制剂治疗。分别有48.4%和45.0%的患者病情进展并接受了二线治疗，其中最常见的是使用pembrolizumab（61.7%）。结论2020年，日本大多数转移性膀胱癌患者接受了以铂类为基础的一线化疗；然而，超过50%的患者没有接受后续治疗，这凸显出需要新的治疗方案来改善预后并最大限度地发挥一线治疗的优势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.